Bioassay protocol metadata annotation: Proposed standards adoption

IF 2.7 4区生物学 Q2 BIOCHEMICAL RESEARCH METHODS

SLAS Discovery Pub Date : 2024-10-19 DOI:10.1016/j.slasd.2024.100188

Rama Balakrishnan , Ellen L. Berg , Christopher C. Butler , Alex M. Clark , Sheryl P. Denker , Isabella Feierberg , Jason Harris , Timothy P. Ikeda , Samantha Jeschonek , Vladimir A. Makarov , Christopher Southan , Dana Vanderwall , Peter Winstanley

{"title":"Bioassay protocol metadata annotation: Proposed standards adoption","authors":"Rama Balakrishnan , Ellen L. Berg , Christopher C. Butler , Alex M. Clark , Sheryl P. Denker , Isabella Feierberg , Jason Harris , Timothy P. Ikeda , Samantha Jeschonek , Vladimir A. Makarov , Christopher Southan , Dana Vanderwall , Peter Winstanley","doi":"10.1016/j.slasd.2024.100188","DOIUrl":null,"url":null,"abstract":"<div><div>We present a standardized metadata template for assays used in pharmaceutical drug discovery research, according to the FAIR principles. We also describe the use of an automated tool for annotating assays from a variety of sources, including PubChem, commercial assay providers, and the peer-reviewed literature, to this metadata template. Adoption of a standardized metadata template will allow drug discovery scientists to better understand and compare the increasing amounts of assay data becoming available, and will facilitate the use of artificial intelligence tools and other computational methods for analysis and prediction. Since bioassays drive advances in biomedical research, improvements in assay metadata can improve productivity in discovery of new therapeutics, platform technologies, and assay methods.</div></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 8","pages":"Article 100188"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS Discovery","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2472555224000509","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

We present a standardized metadata template for assays used in pharmaceutical drug discovery research, according to the FAIR principles. We also describe the use of an automated tool for annotating assays from a variety of sources, including PubChem, commercial assay providers, and the peer-reviewed literature, to this metadata template. Adoption of a standardized metadata template will allow drug discovery scientists to better understand and compare the increasing amounts of assay data becoming available, and will facilitate the use of artificial intelligence tools and other computational methods for analysis and prediction. Since bioassays drive advances in biomedical research, improvements in assay metadata can improve productivity in discovery of new therapeutics, platform technologies, and assay methods.

查看原文本刊更多论文

生物测定协议元数据注释：建议采用的标准。

我们根据 FAIR 原则为药物发现研究中使用的检测方法提供了一个标准化元数据模板。我们还介绍了一种自动工具的使用情况，该工具可根据该元数据模板对各种来源的化验结果进行注释，包括 PubChem、商业化验提供商和同行评议文献。采用标准化元数据模板将使药物发现科学家能够更好地理解和比较日益增多的化验数据，并促进人工智能工具和其他计算方法在分析和预测中的应用。由于生物检测推动了生物医学研究的进步，因此改进检测元数据可以提高发现新疗法、平台技术和检测方法的效率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

SLAS Discovery Chemistry-Analytical Chemistry

CiteScore

7.00

自引率

3.20%

发文量

审稿时长

39 days

期刊介绍： Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies. SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology. SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).